Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 16OTHER 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Lung Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Advanced Solid Malignancies 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Tiragolumab × 90 days × Clear all
NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

NCT06760481 2026-04-15

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
7 enrolled

Advanced Solid Malignancies

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting
148 enrolled
Gynecologic

Endometrial Neoplasms

NCT06713798 2026-03-23

INDIGO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡